Thatthan Suksombooncharoen
Chiang Mai, 50200, Thailand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
The Impact of the COVID-19 Pandemic on Diagnosis, Treatment, and Survival of Lung Cancer Patients in Thailand from 2019-2021.
Journal: Journal of clinical medicine
Published: February 13, 2026
Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.
Journal: BMJ oncology
Published: January 24, 2026
Prognostic Role of Gut Microbiota and Clinical Parameters in Predicting Survival in Advanced Cholangiocarcinoma Patients Receiving Chemotherapy.
Journal: International journal of medical sciences
Published: January 13, 2026
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 03, 2025
Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study.
Journal: Frontiers in oncology
Published: June 15, 2025
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
Journal: Journal of hepatology
Published: January 27, 2025
The Impact of a Multidisciplinary Team Conference on Non-Small Cell Lung Cancer Care: Time Barriers and Long-Term Outcomes.
Journal: Journal of clinical medicine
Published: August 07, 2024
Dietary Counseling Outcomes in Patients with Lung Cancer in an Upper-Middle-Income Country: An Open-Label Randomized Controlled Trial.
Journal: Journal of clinical medicine
Published: July 28, 2024
Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients.
Journal: PloS one
Published: July 13, 2024
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Journal: The lancet. Gastroenterology & hepatology
Published: January 10, 2024
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Journal: Future oncology (London, England)
Published: September 25, 2023
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Journal: NEJM evidence
Published: August 01, 2022
Last Updated: 09/26/2026